The Precision Medicine Market is estimated to be USD 118.69 billion in 2025, projected to reach USD 400.67 billion by 2033. The U.S. market is expected to grow from USD 45.36 billion in 2025 to USD 153.45 billion by 2033, driven by personalized treatment methods based on genetic profiling and AI diagnostic tools.

Healthcare providers are investing in genomic sequencing and AI tools for personalized treatment. Precision medicine offers tailored therapies, improving accuracy and reducing adverse reactions. Key companies in this market include Illumina, Thermo Fisher, and Roche, shaping patient management in oncology, rare diseases, and chronic disorders.

Precision Medicine Market is segmented by type, technology, application, and end-user. Targeted therapy and Next-Generation Sequencing dominate the market. Oncology holds the highest market share, while Rare & Genetic Disorders show the fastest growth. Hospitals lead in end-user share, while Research Institutes are growing due to AI diagnostics adoption.

North America dominates the Precision Medicine Market, with Asia Pacific showing the fastest growth. Recent developments include Illumina’s partnership for cancer diagnostics and Thermo Fisher’s mass spectrometer launch. Exclusive sections of the report cover regulatory metrics, therapy effectiveness, ecosystem collaboration, clinical trials, and policy incentives driving market momentum. SNS Insider offers a detailed report on the Precision Medicine Market, providing in-depth analysis and outlook for the industry. With a focus on delivering accurate market data and consumer insights, the report aims to help clients make informed decisions in a rapidly changing market landscape. Various research techniques are used to ensure the information is current and reliable.

Read more at GlobeNewswire: Precision Medicine Market Projected to Surpass USD 400.67